Sandoz floats nearly $500M to resolve bulk of lingering US antitrust claims

’Tis the season to resolve long-standing litigation in the U.S. | A week after Johnson & Johnson moved to resolve claims that its Johnson’s Baby Powder caused ovarian cancer, Novartis’ generics and biosimilars spinout Sandoz is plotting its own escape from long-running U.S. litigation, this time tied to antitrust allegations.